Caprolactam Chemicals Limited CIN No. L24110MH1988PLC049683

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH SEPTEMBER ,2019

PA	RTI						(Rs. In Lacs)
	PARTICULARS	Quarter End	led		6Months En	ded	Year Ended
		(Unaudited)			(Unaudited)		(Audited)
		30-09-2019	30-06-2019	30-09-2018	30-09-2019		31-03-2019
1	Revenue From Operation	00 07 2017	00 00 2015	20 09 2010	20 07 2017	20 07 2010	21-02-2015
•	Revenue from Operations	117 522	237.282	54.150	354 905	112.072	F10 041
/ + -	Other Income	117.523	AL COLUMN CONTRACTOR		354.805	113.973	
		0.141			0.459	0.273	7.208
	Total Income	117.664	237.600	54.356	355.264	114.245	526.049
2							
(a)	Cost of materials consumed	-7.414	0.502	-38.326	-6.912	-15.318	26.324
(b)	Purchase of stock - I trade	0.000	0.000	0.000	0.000	0.000	0
(c)	Change in inventories of Finished goods, work-in-	0.000	0.000	0.721	0.000	12.082	12.083
(6)	progress and stock-intrade		4.004				
(C)	Employee benefits expenses	5.353	4.864	5.137	10.217	10.092	22.703
(d)	Finance Costs	6.749	8.099	9.955	14.848	15.285	34.128
(e)	Depreciation, depletion and amortisation	28.090	27.340	26.434	55.430	44.429	96.840
(f)	expenses Other expenses			8			
(f)		44.055	17.006	12.551	22.052	20.472	
	(1) Other expenses	14.957	17.906	13.651	32.863	30.173	55.584
	(2) Utility	6.913	5.436	7.210	12.349	7.210	15.385
	(3) Electricity expenses	13.709	30.927	3.261	44.635	6.809	80.477
	(4) Labour	28.035	19.656	4.734	47.691	4.734	68.800
	(5) Repair	15.374	11.552	0.000	26.926	5.566	29.256
	(6) Spare Tools	7.705	7.154	40.711	14.859	46.477	20.050
	Total other expenses	86.693	92.631	69.567	179.323	100.969	269.552
	Total expenses	119.471	133.436	73.488	252.906	167.539	461.630
3	Profit / (Loss) before exceptional items and tax	-1.807	104.164	-19.132	102.358	-53.294	64.419
4	Exceptional items		0.000	0.000	0.000	0.000	0.000
5	Profit before tax	-1.807	104.164	-19.132	102.358	-53.294	64.419
6	Tax expense			2			are and the
	Current tax	0.000	0.000	0.000	0.000	0.000	12.500
	Defered tax	0.000	0.000	0.000	0.000	0.000	1.755
	Total tax expenses	0.000	0.000	0.000	0.000	0.000	14.255
7	Net movement in regulatory deferral account	0.000	0.000	0.000	0.000	0.000	0.000
227	balances related to profit or loss and the related	0.000	0.000	0.000	0.000	0.000	0.000
TOME	deferred tax movement	W == 1					
8	Net Profit Loss for the period from continuing	-1.807	104.164	-19.132	102.358	-53.294	50.164
	operations			0.7			
9	Profit (loss) from discontinued operations before	0.000	0.000	0.000	0.000	0.000	0.000
	tax						
	Tax expense of discontinued operations	0.000	0.000	0.000	0.000	0.000	0.000
11	Net profit (loss) from discontinued operation	0.000	0.000	0.000	0.000	0.000	0.000
12	after tax Share of profit (loss) of associates and joint	0.000	0.000	0.000	0.000	0.000	0.000
. 19	ventures accounted for using equity method	0.000	0.000	0.000	0.000	0.000	0.000
13	Ventures accounted for using equity method Total profit (loss) for period	-1.807	104.164	-19.132	102.358	-53.294	50.164
	Other comprehensive income net of taxes	0.000	0.000	0.000	0.000	0.000	0.000
15	Total Comprehensive Income for the period	-1.807	104.164	-19.132	102.358		
-		- Anna Paris	Para la			-53.294	50.164
16	Total profit or loss, attributable to	0,000	0.000	0.000	0.000	0.000	0.000

17	Profit or loss, attributable to owners of parent	0.000	0.000	0.000	0.000	0.000	0.000
18	Total profit or loss, attributable to non- controlling interests	0.000	0.000	0.000	0.000	0.000	0.000
19	Total Comprehensive income for the period attributable to	0.000	0.000	0.000	0.000	0.000	0.000
20	Comprehensive income for the period attributable to owners of parent	0.000	0.000	0.000	0.000	0.000	0.000
	Total comprehensive income for the period attributable to owners of parent non-controlling interests	0.000	0.000	0.000	0.000	0.000	0.000
22	Details of equity share capital						
	Paid-up equity share capital	460.000	460.000	459.030	460.000	459.030	460.000
	Face value of equity share capital	10.000	10.000	10.000	10.000	10.000	10.000
23	Details of debt securities						
24	Reserves excluding revaluation reserve						-205.515
25	Earnings per share						
26	Earnings per equity share for continuing						III SOWII WALL
	operations						
	Basic earnings (loss) per share from	-0.039	2.264	-0.417	2.225	-1.161	1.091
	continuing operations				100000000000000000000000000000000000000		
	Diluted earnings (loss) per share from	-0.039	2.264	-0.417	2.225	-1.161	1.091
	continuing operations			- 1		1	
27	Earnings per equity share for discontinued						
	operations						
	Basic earnings (loss) per share from	0.000	0.000	0.00	0.00	0.00	0.000
	discontinued operations		2				
	Diluted earnings (loss) per share from	0.000	0.000	0.000	0.000	0.000	0.000
	discontinued operations						
28	Earnings per equity share						
	Basic earnings (loss) per share from continuing	-0.039	2.264	-0.417	2.225	-1.161	1.091
	and discontinued operations				ACEAC VACOS	90000000000000000000000000000000000000	
	Diluted earnings (loss) per share from continuing	-0.039	2.264	-0.417	2.225	-1.161	1.091
	and discontinued operations						2.77
29	Debt equity ratio						
1000	Debt service coverage ratio						
31	Interest service coverage ratio						
27	Disclosure of notes on finance results						in the land of the

- 1. The above results were reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 13th November, 2019 and have been subjected to limited review by the Auditors.
- 2) The format of unaudited quarterly results as prescribed by SEBI's Circuler CIR/CFD/CMD/15/2015 dated 30th November2015 has been modified to comply wih the requirements of SEBI Circuler dated 5th July 2016, Ind AS and Schedule III to the Companies Act,2013.
- 3) As the Company's business activity falls within single significant business segment, viz." Manufacturing" no seprate segment information is enclosed.
- 4) There is no investors complain pending with the company.
- 5) Previous year figures have been regrouped wherever necessary.

Place: Mahad

Date: 13/11/2019

FOR AND BEHALF OF THE BOARD OF DIRECTORS

Ars. Zaver S Bhanushali Managing Director

CAPROLACTAM CHEMICALS LIMITED

(Amount in Rs. in lacs)

	Standalana Statement of Assats and Linkillities	Davied anded As at I	(Amount in Rs. in lacs
	Standalone Statement of Assets and Liabilities	Period ended As at	Period ended As at
	Particulars	30-09-2019	31-03-2019
		Anaudited	Audited
	ASSETS		
	Non-current assets		
	Property, plant and equiment	603.440	636.782
	Capital work-in-progress		
	Investment property		
	Goodwill		
	Other intangible assets		
	Intangible assets under development		
	Biological assets other than bearer plants		
	Investments accounted for using equity method		
	Non-current financial assets		
	Non-current investments		
	Tradereceivable, non-current		
	Loans, non-current	£1	
	Other non-current financial assets		
Tie.	Total non-current financial assets		
	Deferred tax assets(net)		
	Other non-current assets		
	Total non-current assets	603.440	636.782
2	Current assets		
	Inventories	16.123	9.211
жерир	Current financial assets		
	Current investments		V 4
	Trade receivables	51.914	3.983
	Cash and cash equivalents	14.756	15.989
	Bank balance other than cash and cash equivalents	11.217	15.920
	loans, current		
	Other current financial assets	33.948	58.777
	Total Current financial assets	111.835	94.669
	Current tax assets (net)		
	Other current assets		
	Total current assets	127.958	103.880
3	Non-current assets classified as held for sale		
	Regulatory deferral account debit balances and		
	related deferred tax assets		
7.0	Total assets	731.398	740.662
	EQUITY AND LIABILITIES		
1	Equity		
	Equity attributable to owners of parent		
	Equity share capital	460.000	460
	Other equity	-103.158	-205.515
		356.842	254.485

Total equity	356.842	254.48					
2 Liablities							
Non-current liabilities							
Non-current financial liabilities							
Borrowings, non-current							
Trade paybles, non-current	-min = 17 12 3- 14						
Other non-current financial liablities							
Total non-current financial liablities							
Provisions, non-current							
Deferred tax liablities (net)	24.307	24.30					
Deferred government grants, Non -current							
Total non-current liabilities	24.307	24.30					
Current liabilities							
Current financial liabilities							
Borrowings, current	230.645	327.64					
Trade paybles, current	64.710	80.52					
Other current financial liablities	54.284	41.19					
Total current financial liablities	349.639	449.37					
Other current liablities							
Provisions, current	0.250	0.00					
Current tax liablities (net)	0.360	12.50					
Deferred government grants, current							
Total current liablities	350.249	461.87					
3 Liablities directly associated with assets in disposal							
group classified as held for sale	The state of the s						
Regulatory deferral account credit balances and							
related deferred tax laiblity	374.556	106 17					
Total liabilities		486.17					
Total equity and liablities	731.398	740.66					
Disclosure of notes on assets and liablities							
1. The results of the quarter ended 30 September, 2019 were reviewed by the Audit Committee							
and approved by the Board of Directors at their respective meetings held on 13th November, 2019							
2. Previous Year Figures have been regrouped wherever necessary.							
Disco Maked	500 0400 40T444 045						
Place: Mahad	FOR CAROLACTAM CHEI	VIICALS LIMITE					
24/3 WW							
Date: 13/11/2019	- MANA	GING DIRECTO					

Be



Limited Review Report

To Board of Directors Caprolactam Chemicals Limited

We have reviewed the accompanying statement of unaudited financial results of Caprolactam Chemicals Limited for the quarter and six month ended 30th September ,2019 except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. The statement has been prepared by the pursuant to Regulation 33 of the SEBI (Listing Regulations and Disclosure Requirements)Regulation , 2015 (" the Listing Regulations , 2015) This statement is the responsibility of the Company's Management and has been approved by the Board of Directors at the meeting held on 13Th November 2019 . Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have performed an audit and accordingly, we express an unqualified audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of audited financial results prepared in accordance with applicable accounting standards Notified under companies Act 2013 (which are deemed to be applicable as per Section 133 of companies Act 2013, read with Rule 7 of the companies (accounts) Rules, 2014 and other recognized accounting practices and policies, generally accepted in India, has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

Date: 13th November 2019

Place: Mumbai

For Bipin Kothari and Associates **Chartered Accountants**

Proprietor

UDIN:- 19155037AAAADA2479

📱 +91 9870948284 📞 +91 8355904949 / 022 25296138 🐞 cabipinkothari@gmail.com

www.cabipinkothari.com